HCPLive Network

New Agent Significantly Improves Progression-Free Survival in Patients With Advanced ER+ Breast Cancer

Combining the investigational PD 0332991 with letrozole as first-line therapy extended progression-free survival in women with advanced estrogen-receptor positive breast cancer.

Click here to view this article.


Further Reading
Xi E. Zheng, MD, PhD, shares her views on young-onset colorectal cancer at 2014 ACG Annual Scientific Meeting in Philadelphia, PA.
The prevalence of familial pancreatic cancer (FPC) is about 9%, and patients with FPC have more precursor lesions and are less likely to smoke than patients with sporadic pancreatic cancer, according to a study published online Oct. 14 in Cancer.
Studying vascular endothelial growth factor could lead to a new type of painkiller, according to a study published in Neurobiology of Disease.
A recommendation by two FDA advisory panels to narrow the official approval for testosterone replacement therapy has won generally favorable reviews from medical organizations, although questions remain about its ultimate impact.
Low-dose computed tomography is a low-cost and cost-effective strategy for screening Medicare beneficiaries for lung cancer, according to a study published in the August issue of American Health & Drug Benefits.
Do longer periods of androgen-deprivation therapy significantly improve prostate cancer survival rates or needlessly impair quality of life for recovering patients?
A blood test can predict what treatment options are best for patients with major depressive disorder, according to a study published in Translational Psychiatry.
More Reading